IL159527A0 - Human dr4 antibodies and uses thereof - Google Patents
Human dr4 antibodies and uses thereofInfo
- Publication number
- IL159527A0 IL159527A0 IL15952702A IL15952702A IL159527A0 IL 159527 A0 IL159527 A0 IL 159527A0 IL 15952702 A IL15952702 A IL 15952702A IL 15952702 A IL15952702 A IL 15952702A IL 159527 A0 IL159527 A0 IL 159527A0
- Authority
- IL
- Israel
- Prior art keywords
- antibodies
- human
- kits
- diagnosis
- articles
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2510/00—Detection of programmed cell death, i.e. apoptosis
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30322001P | 2001-07-03 | 2001-07-03 | |
PCT/US2002/020712 WO2003066661A2 (en) | 2001-07-03 | 2002-06-29 | Human dr4 antibodies and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
IL159527A0 true IL159527A0 (en) | 2004-06-01 |
Family
ID=27734188
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL15952702A IL159527A0 (en) | 2001-07-03 | 2002-06-29 | Human dr4 antibodies and uses thereof |
Country Status (14)
Country | Link |
---|---|
US (2) | US7252994B2 (de) |
EP (2) | EP1409544B1 (de) |
JP (1) | JP4509570B2 (de) |
AT (1) | ATE433996T1 (de) |
AU (2) | AU2002366430B2 (de) |
CA (1) | CA2451680C (de) |
CY (1) | CY1110505T1 (de) |
DE (1) | DE60232660D1 (de) |
DK (1) | DK1409544T3 (de) |
ES (1) | ES2328234T3 (de) |
HK (1) | HK1065323A1 (de) |
IL (1) | IL159527A0 (de) |
PT (1) | PT1409544E (de) |
WO (1) | WO2003066661A2 (de) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7476383B2 (en) * | 2000-05-02 | 2009-01-13 | The Uab Research Foundation | Antibody selective for DR4 and uses thereof |
TWI318983B (en) | 2000-05-02 | 2010-01-01 | Uab Research Foundation | An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof |
US20060062786A1 (en) * | 2000-11-08 | 2006-03-23 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to TRAIL receptors |
US20030228309A1 (en) * | 2000-11-08 | 2003-12-11 | Theodora Salcedo | Antibodies that immunospecifically bind to TRAIL receptors |
US7348003B2 (en) | 2001-05-25 | 2008-03-25 | Human Genome Sciences, Inc. | Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors |
US20050214209A1 (en) * | 2001-05-25 | 2005-09-29 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to TRAIL receptors |
US7361341B2 (en) * | 2001-05-25 | 2008-04-22 | Human Genome Sciences, Inc. | Methods of treating cancer using antibodies that immunospecifically bind to trail receptors |
US20090226429A1 (en) * | 2001-05-25 | 2009-09-10 | Human Genome Sciences, Inc. | Antibodies That Immunospecifically Bind to TRAIL Receptors |
US20050129616A1 (en) * | 2001-05-25 | 2005-06-16 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to TRAIL receptors |
CA2471140A1 (en) * | 2001-12-20 | 2003-07-03 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to trail receptors |
ES2239886B1 (es) * | 2003-11-05 | 2006-12-16 | Universidad De Barcelona | Metodo y aparato para la determinacion de la viabilidad celular. |
EP1774037B1 (de) | 2004-08-06 | 2011-05-11 | Genentech, Inc. | Assays und verfahren unter verwendung von biomarkern |
CN101035912A (zh) | 2004-08-06 | 2007-09-12 | 健泰科生物技术公司 | 使用生物标志的测定法和方法 |
AU2012200602B2 (en) * | 2004-08-06 | 2012-11-08 | Genentech, Inc. | Assays and methods using biomarkers |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
US8029783B2 (en) | 2005-02-02 | 2011-10-04 | Genentech, Inc. | DR5 antibodies and articles of manufacture containing same |
ZA200800974B (en) * | 2005-08-16 | 2009-11-25 | Genentech Inc | Apoptosis sensitivity to Apo2L/TRAIL by testing for 'GalNac-T14 expression in cells/tissues |
JP2007063225A (ja) * | 2005-09-01 | 2007-03-15 | Takeda Chem Ind Ltd | イミダゾピリジン化合物 |
EP1945244B1 (de) * | 2005-10-16 | 2016-05-04 | Yeda Research And Development Co., Ltd. | Verwendung von caspase-8 in pharmazeutischen zusammensetzungen und diagnoseverfahren für entzündliche hauterkrankungen, störungen oder zustände |
JP2009515997A (ja) * | 2005-11-18 | 2009-04-16 | タケダ サン ディエゴ インコーポレイテッド | グルコキナーゼ活性剤 |
US8034822B2 (en) | 2006-03-08 | 2011-10-11 | Takeda San Diego, Inc. | Glucokinase activators |
EP2049518B1 (de) | 2006-05-31 | 2011-08-31 | Takeda San Diego, Inc. | Indazol- und isoindolderivate als glucokinaseaktivierende stoffe |
WO2008079787A2 (en) | 2006-12-20 | 2008-07-03 | Takeda San Diego, Inc. | Glucokinase activators |
US8173645B2 (en) * | 2007-03-21 | 2012-05-08 | Takeda San Diego, Inc. | Glucokinase activators |
WO2011159928A2 (en) * | 2010-06-16 | 2011-12-22 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Anti-dr4 agonist antibodies |
CN109022465B (zh) | 2011-10-28 | 2022-04-29 | 特瓦制药澳大利亚私人有限公司 | 多肽构建体及其用途 |
EP2684896A1 (de) | 2012-07-09 | 2014-01-15 | International-Drug-Development-Biotech | Antikörper gegen die DR5-Familie, bispezifische oder multivalente Antikörper gegen die DR5-Familie und Verfahren zu deren Verwendung |
UA113129C2 (xx) | 2013-04-29 | 2016-12-12 | ЗЛИТА КОНСТРУКЦІЯ АНТИТІЛО ПРОТИ CD38 З ОСЛАБЛЕНИМ ІНТЕРФЕРОНОМ АЛЬФА-2b | |
US11117975B2 (en) | 2013-04-29 | 2021-09-14 | Teva Pharmaceuticals Australia Pty Ltd | Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B |
UA119352C2 (uk) | 2014-05-01 | 2019-06-10 | Тева Фармасьютикалз Острейліа Пті Лтд | Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину |
PE20170908A1 (es) | 2014-10-29 | 2017-07-12 | Teva Pharmaceuticals Australia Pty Ltd | VARIANTES DE INTERFERON a2b |
EP3368076A4 (de) * | 2015-10-30 | 2019-08-28 | Galaxy Biotech, LLC | An death-rezeptor 4 und 5 bindende hochwirksame antikörper |
CN108884158A (zh) | 2015-12-01 | 2018-11-23 | 根马布有限公司 | 抗死亡受体抗体及其使用方法 |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8905669D0 (en) * | 1989-03-13 | 1989-04-26 | Celltech Ltd | Modified antibodies |
EP0417563B1 (de) | 1989-09-12 | 2000-07-05 | F. Hoffmann-La Roche Ag | TNF-bindende Proteine |
AU1368292A (en) | 1991-03-11 | 1992-10-06 | Sheila Drover | Murine monoclonal antibodies recognizing polymorphic determinants of hla |
US5397703A (en) * | 1992-07-09 | 1995-03-14 | Cetus Oncology Corporation | Method for generation of antibodies to cell surface molecules |
AU704440B2 (en) * | 1994-02-04 | 1999-04-22 | Bio Merieux | MSRV1 virus and MSRV2 pathogenic and/or infectious agent associated with multiple sclerosis, nucleic acid components and applications of same |
ES2253753T3 (es) | 1995-06-29 | 2006-06-01 | Immunex Corporation | Citocina que induce apoptosis. |
US6030945A (en) | 1996-01-09 | 2000-02-29 | Genentech, Inc. | Apo-2 ligand |
ATE302272T1 (de) | 1996-10-25 | 2005-09-15 | Human Genome Sciences Inc | Neutrokin alpha |
CA2274987C (en) | 1996-12-23 | 2012-01-24 | Immunex Corporation | Ligand for receptor activator of nf-kappa b, ligand is member of tnf superfamily |
AU6250098A (en) * | 1997-01-28 | 1998-08-18 | Human Genome Sciences, Inc. | Death domain containing receptor 4 (dr4: death receptor 4), member of the tnf-receptor superfamily and binding to trail (ap02-l) |
US6433147B1 (en) * | 1997-01-28 | 2002-08-13 | Human Genome Sciences, Inc. | Death domain containing receptor-4 |
US6072047A (en) | 1997-02-13 | 2000-06-06 | Immunex Corporation | Receptor that binds trail |
US5969102A (en) | 1997-03-03 | 1999-10-19 | St. Jude Children's Research Hospital | Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof |
US20010010924A1 (en) | 1997-03-14 | 2001-08-02 | Keith Charles Deen | Tumor necrosis factor related receptor, tr6 polynecleotides |
CN1184315C (zh) | 1997-03-17 | 2005-01-12 | 人类基因组科学公司 | 包含死亡结构域的受体-5 |
JP2002512515A (ja) | 1997-04-16 | 2002-04-23 | ミレニアム ファーマシューティカルズ インク. | 腫瘍壊死因子受容体関連蛋白質TANGO−63dおよびTANGO−63e |
ATE363533T1 (de) | 1997-04-16 | 2007-06-15 | Amgen Inc | Osteoprotegerin bindende proteine und rezeptoren |
DK1860187T3 (da) | 1997-05-15 | 2011-10-31 | Genentech Inc | Apo-2-receptor |
AU8400398A (en) | 1997-07-11 | 1999-02-08 | Trustees Of The University Of Pennsylvania, The | Nucleic acid encoding a novel chemotherapy-induced protein, and methods of use |
AU9013998A (en) | 1997-07-21 | 1999-02-10 | Zymogenetics Inc. | Tumor necrosis factor receptor ztnfr-5 |
EP1019502A2 (de) | 1997-08-06 | 2000-07-19 | Regeneron Pharmaceuticals, Inc. | Humane waisenrezeptor ntr-1 |
CA2301202A1 (en) | 1997-08-15 | 1999-02-25 | Idun Pharmaceuticals, Inc. | Trail receptors, nucleic acids encoding the same, and methods of use thereof |
AU9376498A (en) | 1997-09-05 | 1999-03-22 | University Of Washington | Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents |
AU2093499A (en) | 1997-12-30 | 1999-07-19 | Chiron Corporation | Members of tnf and tnfr families |
US20040120947A1 (en) * | 1998-01-26 | 2004-06-24 | Genentech, Inc. | DR4 antibodies and uses thereof |
US20040180049A1 (en) * | 1998-01-26 | 2004-09-16 | Genentech, Inc. | DR4 antibodies and uses thereof |
AU2338299A (en) * | 1998-01-26 | 1999-08-09 | Genentech Inc. | Antibodies to death receptor 4 (dr4) and uses thereof |
DE69941453D1 (de) | 1998-06-12 | 2009-11-05 | Genentech Inc | Monoklonale antikörper, kreuz-reaktive antikörper und deren produktionsverfahren |
US6252050B1 (en) * | 1998-06-12 | 2001-06-26 | Genentech, Inc. | Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method |
WO2000073349A1 (en) * | 1999-05-28 | 2000-12-07 | Genentech, Inc. | Dr4 antibodies and uses thereof |
US7291714B1 (en) * | 1999-06-30 | 2007-11-06 | Millennium Pharmaceuticals, Inc. | Glycoprotein VI and uses thereof |
US7279160B2 (en) * | 2000-05-02 | 2007-10-09 | The Uab Research Foundation | Combinations of DR5 antibodies and other therapeutic agents |
US7115717B2 (en) * | 2001-05-18 | 2006-10-03 | Kirin Beer Kabushiki Kaisha | Anti-TRAIL-R antibodies |
KR100942393B1 (ko) | 2001-05-25 | 2010-02-17 | 휴먼 게놈 사이언시즈, 인코포레이티드 | Trail 수용체에 면역특이적으로 결합하는 항체 |
ES2357225T3 (es) | 2001-11-01 | 2011-04-20 | Uab Research Foundation | Combinaciones de anticuerpos anti-dr5 y anticuerpos anti-dr4 y otros agentes terapéuticos. |
CN100506277C (zh) | 2001-11-01 | 2009-07-01 | Uab研究基金会 | 肿瘤坏死因子相关细胞凋亡诱导配体受体的选择性抗体和其它治疗剂的联合体系 |
AU2002352676A1 (en) | 2001-11-14 | 2003-05-26 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to trail receptors |
-
2002
- 2002-06-29 JP JP2003566032A patent/JP4509570B2/ja not_active Expired - Lifetime
- 2002-06-29 AU AU2002366430A patent/AU2002366430B2/en not_active Expired
- 2002-06-29 AT AT02805988T patent/ATE433996T1/de active
- 2002-06-29 WO PCT/US2002/020712 patent/WO2003066661A2/en active Search and Examination
- 2002-06-29 DE DE60232660T patent/DE60232660D1/de not_active Expired - Lifetime
- 2002-06-29 CA CA2451680A patent/CA2451680C/en not_active Expired - Lifetime
- 2002-06-29 US US10/480,730 patent/US7252994B2/en not_active Expired - Lifetime
- 2002-06-29 EP EP02805988A patent/EP1409544B1/de not_active Expired - Lifetime
- 2002-06-29 PT PT02805988T patent/PT1409544E/pt unknown
- 2002-06-29 DK DK02805988T patent/DK1409544T3/da active
- 2002-06-29 EP EP09004361A patent/EP2192130A1/de not_active Withdrawn
- 2002-06-29 ES ES02805988T patent/ES2328234T3/es not_active Expired - Lifetime
- 2002-06-29 IL IL15952702A patent/IL159527A0/xx active IP Right Grant
-
2004
- 2004-10-14 HK HK04107906.4A patent/HK1065323A1/xx not_active IP Right Cessation
-
2007
- 2007-06-28 US US11/819,575 patent/US7744881B2/en active Active
-
2008
- 2008-12-18 AU AU2008260311A patent/AU2008260311A1/en not_active Abandoned
-
2009
- 2009-08-19 CY CY20091100882T patent/CY1110505T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
WO2003066661A3 (en) | 2003-11-27 |
US20080233646A1 (en) | 2008-09-25 |
CY1110505T1 (el) | 2015-04-29 |
CA2451680C (en) | 2011-04-19 |
DK1409544T3 (da) | 2009-10-26 |
WO2003066661A2 (en) | 2003-08-14 |
ATE433996T1 (de) | 2009-07-15 |
US20040147725A1 (en) | 2004-07-29 |
JP2005517021A (ja) | 2005-06-09 |
AU2008260311A1 (en) | 2009-01-15 |
AU2002366430B2 (en) | 2008-09-18 |
PT1409544E (pt) | 2009-09-16 |
EP1409544A4 (de) | 2005-11-09 |
ES2328234T3 (es) | 2009-11-11 |
CA2451680A1 (en) | 2003-08-14 |
EP1409544B1 (de) | 2009-06-17 |
JP4509570B2 (ja) | 2010-07-21 |
AU2002366430A1 (en) | 2003-09-02 |
DE60232660D1 (de) | 2009-07-30 |
US7744881B2 (en) | 2010-06-29 |
EP2192130A1 (de) | 2010-06-02 |
EP1409544A2 (de) | 2004-04-21 |
HK1065323A1 (en) | 2005-02-18 |
US7252994B2 (en) | 2007-08-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1065323A1 (en) | Human dr4 antibodies and uses thereof | |
IL146448A0 (en) | Dr4 antibodies and uses thereof | |
CY1111863T1 (el) | Αντισωματα εναντιον υποδοχεα θανατου 4 (dr4) και χρησεις αυτων | |
CY2020003I1 (el) | Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις για την θεραπευτικη αγωγη της παθολογιας του crohn | |
WO2004011611A3 (en) | Taci antibodies and uses thereof | |
IL127558A0 (en) | Hepatocyte growth factor receptor agonists and uses thereof | |
MXPA02011656A (es) | Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos. | |
MXPA02001911A (es) | Anticuerpos ctla-4 humanos y sus usos. | |
GB0421639D0 (en) | Methods and compositions relating to alzheimer's disease | |
MY136095A (en) | Use of human anti-ctla-4 antibodies for treatment of cancer | |
IL216579A0 (en) | Aminocyclohexyl ether derivatives and pharmaceutical compositions containing the same | |
EP2292666A3 (de) | Neoplasma-spezifische Antikörper und deren Verwendungen | |
WO2004009029A3 (en) | Compositions and methods for treating and preventing infection | |
WO2002066492A3 (fr) | Anticorps specifique de l'adrenomedulline humaine, composition pharmaceutique le contenant, ses applications therapeutiques. | |
WO2003044047A3 (en) | Virulence proteins of the genus yersinia and uses thereof | |
NZ514691A (en) | Method to type prion proteins | |
EP1370697A4 (de) | Peroxiredoxin-arzneistoffe zur behandlung einer hiv-1-infektion und verfahren zu deren verwendung | |
AU2002316158A1 (en) | Methods and compounds for the diagnosis of inflammatory disease and identification of pharmacological agents | |
WO2003027295A3 (en) | Methods for diagnosis and treatment of diseases associated with altered expression of jak1 | |
AU2002239505A1 (en) | Methods and compositions for the diagnosis and treatment of viral disease using 55092 | |
EP1184465A3 (de) | Verfahren zur Diagnose von Polymorphismen des humanen MCT-1 Gens sowie hierdurch definierte Wirkstoffe | |
MY157231A (en) | Aminocyclohexyl ether compounds and uses thereof | |
ZA200301143B (en) | Biological materials and methods useful in the diagnosis and treatment of diseases. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
KB | Patent renewed | ||
KB | Patent renewed | ||
KB | Patent renewed |